Krystal Biotech Inc. (KRYS:NASDAQ) received a biologics license application PDUFA date of May 19, 2023, from the U.S. Food & Drug Administration (FDA) for B-VEC, an investigational topical gene therapeutic for dystrophic epidermolysis bullosa, reported H.C. Wainwright & Co. analyst Dr. Joseph Pantginis in a Feb. 27 research note. The company also submitted a marketing authorization application for B-VEC to the European Medicines Agency.
"We reiterate our confidence in a positive FDA review (that is also reflected in our valuation) and believe Krystal is well-equipped and prepared to successfully launch in the U.S. and the European Union upon respective regulatory acceptances," Pantginis commented.
Full Approval Expected
H.C. Wainwright expects B-VEC to get full approval, the analyst added, based on the strongly supportive safety and efficacy data behind it.
Krystal's B-VEC program for dystrophic epidermolysis bullosa accounts for 89% of H.C. Wainwright's valuation of Krystal, on which the financial institution has a Buy rating and a US$119 per share price target. In comparison, Krystal's current share price is about US$78.46.
"We believe potential upside exists as clinical data are delivered from [KB105 for autosomal recessive congenital ichthyosis and KB301 for wrinkles/acne scars] and [from] potential contributions from pipeline development," wrote Pantginis.
Also, the analyst highlighted, the Pennsylvania-based biotech continues to advance various therapeutic candidates in its pipeline and has several related, catalysts on the horizon.
In H1/23, the biotech plans to launch two clinical studies. One is the Phase 1 CORAL-1 trial to evaluate KB407, a gene therapy aimed at correcting the underlying cause of cystic fibrosis. The other is a Phase 2 trial to evaluate KB105 in pediatric and adult patients with the skin disorder, TGM1-deficient autosomal recessive congenital ichthyosis.
Later this year, also in its dermatology program, Krystal plans another trial of KB301, an investigational gene-based treatment of aesthetic skin conditions, such as fine lines and wrinkles. Called PEARL-2, it will be a Phase 2 study of this lead drug candidate in patients with lateral canthal lines on "challenging areas of the face," noted Pantginis. PEARL-1, the precursor study, showed "encouraging efficacy for those with aesthetic skin conditions," reported Pantginis. Specifically, KB301 demonstrated durability for up to nine months.
"With these results in hand and the totality of the positive results from the PEARL-1 study, we have continued confidence in the success of KB301 within the aesthetic space," Pantginis wrote.
Latest Financial Results
In other news, reported Pantginis, Krystal ended 2022 "financially strong," with US$383.8 million in cash on the balance sheet.
The biotech's earnings per share (EPS) for Q4/22 was (US$1.25), in line with H.C. Wainwright and consensus' estimates of (US$1.24) and ($1.32), respectively.
Similarly, full-year 2022 EPS of (US$5.49) also was expected. H.C. Wainwright's forecast was (US$5.48) and the Street's, (US$5.41).
|Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter.||Subscribe|
1) Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Statements and opinions expressed are the opinions of the author and not of Streetwise Reports or its officers. The author is wholly responsible for the validity of the statements. The author was not paid by Streetwise Reports for this article. Streetwise Reports was not paid by the author to publish or syndicate this article. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
Disclosures For H.C. Wainwright & Co., Krystal Biotech Inc., February 27, 2023
H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer.
I, Joseph Pantginis, Ph.D., Matthew Keller, Ph.D. and Sara Nik, Ph.D. , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.
None of the research analysts or the research analyst’s household has a financial interest in the securities of Krystal Biotech, Inc. (including, without limitation, any option, right, warrant, future, long or short position). As of January 31, 2023 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Krystal Biotech, Inc..
Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report.
The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. The firm or its affiliates received compensation from Krystal Biotech, Inc. for non-investment banking services in the previous 12 months.
The Firm or its affiliates did not receive compensation from Krystal Biotech, Inc. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report. The Firm does not make a market in Krystal Biotech, Inc. as of the date of this research report. The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited.
This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request.
H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report.
H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.
The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice. Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.